ZBTB38 and metastatic prostate carcinoma: Monitoring ZBTB38 expression level in tumours might thus be useful, in combination with other genetic alterations (i.e., SPOP/SPOPL), to target metastatic prostate cancer with doxorubicin-based therapies.